Puxin Biotech

Puxin Biotech is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the discovery and development of next-generation Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company's primary focus is on treating hematological malignancies, including various forms of leukemia and lymphoma, through its robust pipeline of autologous cell products. Puxin Biotech utilizes advanced genetic engineering and optimized manufacturing protocols to enhance the persistence and anti-tumor activity of its therapeutic candidates. With several programs in Phase 1 and Phase 2 clinical trials, the company is positioning itself as a significant player in the Chinese cell therapy landscape. Their lead candidate, PX-19, is currently being evaluated for its efficacy in patients with relapsed or refractory B-cell lymphomas.